BIIB Quote, Financials, Valuation and Earnings

Amgen, Inc. has a net margin of -2.24% compared to Biogen, Inc.'s net margin of 13.47%. Biogen, Inc.'s return on equity of 7.36% beat Amgen, Inc.'s return on equity of 102.03%.

Biogen, Inc. has a consensus price target of $207.33, signalling upside risk potential of 16.74%. On the other hand Amgen, Inc. has an analysts' consensus of $350.41 which suggests that it could grow by 0.75%. Given that Biogen, Inc. has higher upside potential than Amgen, Inc., analysts believe Biogen, Inc. is more attractive than Amgen, Inc..

Biogen, Inc. has a beta of 0.162, which suggesting that the stock is 83.797% less volatile than S&P 500. In comparison Amgen, Inc. has a beta of 0.471, suggesting its less volatile than the S&P 500 by 52.947%.

Biogen, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amgen, Inc. offers a yield of 2.82% to investors and pays a quarterly dividend of $2.52 per share. Biogen, Inc. pays -- of its earnings as a dividend. Amgen, Inc. pays out 66.92% of its earnings as a dividend. Amgen, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Biogen, Inc. quarterly revenues are $2.2B, which are smaller than Amgen, Inc. quarterly revenues of $9.9B. Biogen, Inc.'s net income of -$48.9M is lower than Amgen, Inc.'s net income of $1.3B. Notably, Biogen, Inc.'s price-to-earnings ratio is 19.43x while Amgen, Inc.'s PE ratio is 24.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biogen, Inc. is 2.63x versus 5.05x for Amgen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of -2.24% compared to Biogen, Inc.'s net margin of 34.4%. Biogen, Inc.'s return on equity of 7.36% beat Eli Lilly & Co.'s return on equity of 104.39%.

Biogen, Inc. has a consensus price target of $207.33, signalling upside risk potential of 16.74%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,209.21 which suggests that it could grow by 29.25%. Given that Eli Lilly & Co. has higher upside potential than Biogen, Inc., analysts believe Eli Lilly & Co. is more attractive than Biogen, Inc..

Biogen, Inc. has a beta of 0.162, which suggesting that the stock is 83.797% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.506, suggesting its less volatile than the S&P 500 by 49.45%.

Biogen, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.68% to investors and pays a quarterly dividend of $1.73 per share. Biogen, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 26.14% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Biogen, Inc. quarterly revenues are $2.2B, which are smaller than Eli Lilly & Co. quarterly revenues of $19.3B. Biogen, Inc.'s net income of -$48.9M is lower than Eli Lilly & Co.'s net income of $6.6B. Notably, Biogen, Inc.'s price-to-earnings ratio is 19.43x while Eli Lilly & Co.'s PE ratio is 40.61x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biogen, Inc. is 2.63x versus 12.82x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of -2.24% compared to Biogen, Inc.'s net margin of 18.15%. Biogen, Inc.'s return on equity of 7.36% beat Merck & Co., Inc.'s return on equity of 36.76%.

Biogen, Inc. has a consensus price target of $207.33, signalling upside risk potential of 16.74%. On the other hand Merck & Co., Inc. has an analysts' consensus of $128.59 which suggests that it could grow by 6.11%. Given that Biogen, Inc. has higher upside potential than Merck & Co., Inc., analysts believe Biogen, Inc. is more attractive than Merck & Co., Inc..

Biogen, Inc. has a beta of 0.162, which suggesting that the stock is 83.797% less volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.266, suggesting its less volatile than the S&P 500 by 73.446%.

Biogen, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 2.74% to investors and pays a quarterly dividend of $0.85 per share. Biogen, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 45.05% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Biogen, Inc. quarterly revenues are $2.2B, which are smaller than Merck & Co., Inc. quarterly revenues of $16.3B. Biogen, Inc.'s net income of -$48.9M is lower than Merck & Co., Inc.'s net income of $3B. Notably, Biogen, Inc.'s price-to-earnings ratio is 19.43x while Merck & Co., Inc.'s PE ratio is 16.64x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biogen, Inc. is 2.63x versus 4.67x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of -2.24% compared to Biogen, Inc.'s net margin of -9.34%. Biogen, Inc.'s return on equity of 7.36% beat Pfizer Inc.'s return on equity of 8.69%.

Biogen, Inc. has a consensus price target of $207.33, signalling upside risk potential of 16.74%. On the other hand Pfizer Inc. has an analysts' consensus of $28.58 which suggests that it could grow by 0.92%. Given that Biogen, Inc. has higher upside potential than Pfizer Inc., analysts believe Biogen, Inc. is more attractive than Pfizer Inc..

Biogen, Inc. has a beta of 0.162, which suggesting that the stock is 83.797% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.433, suggesting its less volatile than the S&P 500 by 56.687%.

Biogen, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.12% to investors and pays a quarterly dividend of $0.43 per share. Biogen, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 126.85% of its earnings as a dividend.

Biogen, Inc. quarterly revenues are $2.2B, which are smaller than Pfizer Inc. quarterly revenues of $17.6B. Biogen, Inc.'s net income of -$48.9M is higher than Pfizer Inc.'s net income of -$1.6B. Notably, Biogen, Inc.'s price-to-earnings ratio is 19.43x while Pfizer Inc.'s PE ratio is 20.74x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biogen, Inc. is 2.63x versus 2.56x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.